Association of International Accountants

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
FDA, Research and development, Trial of the century, IND, American College, Association of International Accountants, Food, 2023 International Conference on Climate Resilient Pakistan, ACAAI, Conference, Asthma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hereditary angioedema, R, Bank statement, HAE, American College of Allergy, Asthma and Immunology, ACIS, Abstract, Record, Safety, Attack, Patient, International Accounting Standards Board, Communication, Book, Administration, CIIC, Pharmaceutical industry, Cryptocurrency, Allergy

Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.

Key Points: 
  • Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.
  • R&D expenses were €18.5 million for the quarter ended September 30, 2023, compared to €14.1 million for the quarter ended September 30, 2022.
  • G&A expenses were €7.7 million for the quarter ended September 30, 2023, compared to €8.3 million for the quarter ended September 30, 2022.
  • Details are as follows:
    Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

CloudMD Reports Second Quarter 2023 CloudMD Continues to Drive Execution with Adjusted EBITDA Approaching Breakeven

Retrieved on: 
Monday, August 28, 2023
Partnership, International, Association of International Accountants, Hospital, Calfrac Well Services, Practice management software, Electronic health record, COVID-19, Patient, International Financial Reporting Standards, Eastman Kodak Co. v. Image Technical Services, Inc., XTM, OTCQX, Growth, Remote patient monitoring, International Accounting Standards Board, Bookkeeping, Health insurance, Pharmaceutical industry, Airline, Rare-earth element, Health, Telehealth, Adjustment, Kii

This was CloudMD’s third consecutive quarter of improving Adjusted EBITDA, representing a $2.5 million improvement year over year.

Key Points: 
  • This was CloudMD’s third consecutive quarter of improving Adjusted EBITDA, representing a $2.5 million improvement year over year.
  • On August 23rd, 2023, CloudMD announced the signing of a significant contract to provide Remote Patient Monitoring to a major U.S.
  • Both Gross Margin and Adjusted EBITDA have seen continuous improvement quarter over quarter and our goal for Adjusted EBITDA breakeven in Q4 2023 is within reach.
  • Q2 2023 Adjusted EBITDA1 of ($0.7) million, compared to Adjusted EBITDA1 of ($1.4) million in Q1 2023 and compared to ($3.2) million in Q2 2022.

Grant Thornton appoints new leaders to its Audit Quality & Risk leadership team

Retrieved on: 
Thursday, August 10, 2023
Professional Services, Other Professional Services, Small Business, Finance, Consulting, Banking, Accounting, Risk, Grant Thornton International, University, Moses Austin, Association of International Accountants, International, Decker, Salisbury University, Face, Comptroller, Generally Accepted Accounting Principles (United States), Certified Public Accountant, American Institute of Certified Public Accountants, Professional practice of behavior analysis, AICPA, Assurance services, Financial Accounting Standards Board, CPA, International Accounting Standards Board, American Institute, Audit, Independence, Grant

Grant Thornton LLP, one of America’s largest audit, tax and advisory firms, today announced that it has appointed two new leaders to the firm’s Audit Quality & Risk practice.

Key Points: 
  • Grant Thornton LLP, one of America’s largest audit, tax and advisory firms, today announced that it has appointed two new leaders to the firm’s Audit Quality & Risk practice.
  • Decker assumes her new role from Mary Ropes, an Audit partner at Grant Thornton, who retires after more than 35 years of service at the firm.
  • Dyer assumes his new role from Lynne Triplett, an Audit partner at Grant Thornton, who retires after more than 17 years of service at the firm.
  • Jeff Hughes , Grant Thornton’s national managing partner of Audit Quality and Risk, says the two leaders are positioned to advance the firm’s commitment to quality.

Gravity Reports Second Quarter of 2023 Results and Business Updates

Retrieved on: 
Wednesday, August 9, 2023
Online, KRW, Federal Reserve Bank, Advertising, NFT, International, Association of International Accountants, Google Play, 2009: Lost Memories, Ragnarok Online, App Store (iOS/iPadOS), US, Ragnarök, International Financial Reporting Standards, Active Intelligence Pte Ltd, Yoy, Next Generation, High, Quarter, International Accounting Standards Board, Cryptocurrency, Video game, Gravity

Total revenues were KRW 238,894 million (US$ 181,282 thousand), representing an 44.8% increase from the first quarter ended March 31, 2023 (“QoQ”) and a 147.5% increase from the second quarter ended June 30, 2022 (“YoY”).

Key Points: 
  • Total revenues were KRW 238,894 million (US$ 181,282 thousand), representing an 44.8% increase from the first quarter ended March 31, 2023 (“QoQ”) and a 147.5% increase from the second quarter ended June 30, 2022 (“YoY”).
  • Online game revenues for the second quarter of 2023 were KRW 17,025 million (US$ 12,919 thousand), representing a 25.0% decrease QoQ from KRW 22,696 million and a 31.4% decrease YoY from KRW 24,827 million.
  • Mobile game revenues were KRW 218,687 million (US$ 165,949 thousand) for the second quarter of 2023, representing a 57.3% increase QoQ from KRW 138,994 million and a 221.4% increase YoY from KRW 68,042 million.
  • The presentation contains the Company’s recent business updates, results of the second quarter in 2023 and Gravity’s business plan.

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 7, 2023
Attack, Association of International Accountants, Bank statement, Hereditary angioedema, Foresite Capital, Record, EAACI, Research, Allergy, Trial of the century, HAE, Deficiency, Investigational New Drug, European Academy of Allergy and Clinical Immunology, Patient, Administration, Research and development, General Atlantic, R, FDA, Angioedema, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Book, Food, Safety, International Accounting Standards Board, Vaccine, Pharmaceutical industry, Cryptocurrency

Pharvaris anticipates submitting the results of this nonclinical study to the FDA by the end of 2023.

Key Points: 
  • Pharvaris anticipates submitting the results of this nonclinical study to the FDA by the end of 2023.
  • R&D expenses were €14.7 million for the quarter ended June 30, 2023, compared to €13.7 million for the quarter ended June 30, 2022.
  • G&A expenses were €7.8 million for the quarter ended June 30, 2023, compared to €7.7 million for the quarter ended June 30, 2022.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

ECARX Appoints New Chief Financial Officer

Retrieved on: 
Friday, July 28, 2023
Cloud, Dell, EVP, Head, MBA, Washington University in St. Louis, Science, Association of International Accountants, ECX, Fudan University, Management, Greater China

LONDON, July 28, 2023 (GLOBE NEWSWIRE) -- ECARX Holdings, Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), the global mobility tech provider, today announced that it has appointed Mr. Phil Jing Zhou as its chief financial officer, effective on July 28, 2023.

Key Points: 
  • LONDON, July 28, 2023 (GLOBE NEWSWIRE) -- ECARX Holdings, Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), the global mobility tech provider, today announced that it has appointed Mr. Phil Jing Zhou as its chief financial officer, effective on July 28, 2023.
  • Mr. Zhou will succeed Mr. Ramesh Narasimhan, who will take on the position of advisor to the chief executive officer with effect from the same date.
  • I look forward to him returning to a finance role as the group’s Chief Financial Officer.
  • He joined ECARX in 2021 as chief of staff to the chief executive officer, China chief financial officer and vice president of business operations and has served as executive vice president, China operations since May 2023.

Gravity Reports First Quarter of 2023 Results and Business Update

Retrieved on: 
Thursday, May 11, 2023
Online, KRW, Federal Reserve Bank, Advertising, Blockchain, High, NFT, International, Association of International Accountants, 2009: Lost Memories, MMORPG, RPG, Ragnarok Online, PC, US, Ragnarök, Publishing, Gravity, International Financial Reporting Standards, Yoy, Next Generation, Quarter, International Accounting Standards Board, Cryptocurrency, Video game, Film industry

The game is being prepared to be launched in global in the fourth quarter of 2023.

Key Points: 
  • The game is being prepared to be launched in global in the fourth quarter of 2023.
  • Ragnarok M: Eternal Love aims to be launched in Vietnam in the fourth quarter of 2023.
  • WITH: Whale In The High, a Healing Idle mobile game, is scheduled to be released in global in the second quarter of 2023.
  • The presentation contains the Company’s recent business updates, results of the first quarter in 2023 and Gravity’s business plan.

Enlight Renewable Energy Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Insurance, Maintenance, International, Association of International Accountants, Table, PIN, Safety, Disclosure, Tax, Electricity, Environment, health and safety, Risk, Terrorism, IRA, Forecasting, Government, Wind, Sale, Renewable energy, International Financial Reporting Standards, EBITDA, Climate change, Investment, Disagreement, Annual report, Webcast, Depreciation, Growth, Weather, Environmental Health (journal), Security (finance), Adjustment, Enlight, Articles of association, International Accounting Standards Board, Bookkeeping, Cryptocurrency, Audit

TEL AVIV, Israel, May 11, 2023 (GLOBE NEWSWIRE) -- Enlight Renewable Energy Ltd. (NASDAQ: ENLT, TASE: ENLT) today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • We intend to announce material information to the public through the Enlight investor relations website at https://enlightenergy.co.il/info/investors , SEC filings, press releases, public conference calls, and public webcasts.
  • We use these channels to communicate with our investors, customers, and the public about our company, our offerings, and other issues.
  • This release presents Adjusted EBITDA, a financial metric, which is provided as a complement to the results provided in accordance with the International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”).
  • A reconciliation of the non-IFRS financial information to the most directly comparable IFRS financial measure is provided in the accompanying tables found at the end of this release.

Profound Medical Announces First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
Insurance, Webcast, Travel, International, Association of International Accountants, D, Marketing, S&D, Telephone, G&A, Research, Sale, American Medical Association, MRI, Panel, Prostate, PIN, American Urological Association, International Financial Reporting Standards, United States Army Medical Corps, TSX, R, Safety, International Accounting Standards Board, Pharmaceutical industry, Video game, Cryptocurrency

TORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • TORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2023.
  • First quarter 2023 S&D expenses decreased by 4% to approximately $2.1 million, compared with $2.2 million in the first quarter of 2022.
  • For complete financial results, please see Profound’s filings at www.sedar.com , www.sec.gov and on the Company’s website at www.profoundmedical.com under “Financial” in the Investors section.
  • Profound Medical is pleased to invite all interested parties to participate in a conference call today at 4:30 pm ET during which time the results will be discussed.

Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 8, 2023
Abstract, Bank of America, Attack, Association of International Accountants, Hereditary angioedema, Doctor of Philosophy, Bank statement, Safety, Chief commercial officer, PDT, Record, EAACI, Allergy, European Academy of Allergy and Clinical Immunology, HAE, Deficiency, Administration, CEST, Poster, Commercial, Research and development, Community engagement, Angioedema, R, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Book, Food, International Accounting Standards Board, Cryptocurrency, Pharmaceutical industry

Based on the Company’s current assessment of the ex-U.S. regulatory status and enrollment rates, Pharvaris anticipates announcing top-line data by the end of 2023.

Key Points: 
  • Based on the Company’s current assessment of the ex-U.S. regulatory status and enrollment rates, Pharvaris anticipates announcing top-line data by the end of 2023.
  • Cash and cash equivalents were €135 million as of March 31, 2023, compared to €162 million for December 31, 2022.
  • R&D expenses were €13.7 million for the quarter ended March 31, 2023, compared to €13.5 million for the quarter ended March 31, 2022.
  • G&A expenses were €7.3 million for the quarter ended March 31, 2023, compared to €5.9 million for the quarter ended March 31, 2022.